v3.25.4
Segment Information (Tables)
 12 Months Ended
Dec. 31, 2025
Segment Reporting [Abstract]  
Schedule of Segment Reporting Information, by Segment
The following table summarizes information for our single reportable segment, including significant segment expenses:
202520242023
Revenue$65,179 $45,043 $34,124 
Less:
Cost of sales11,052 8,418 7,082 
Early-stage research and development(1)
4,881 3,917 3,093 
Late-stage research and development(1)
8,456 7,074 6,221 
Marketing, selling, and administrative11,094 8,594 7,404 
Acquired in-process research and development2,910 3,280 3,800 
Other segment items(2)
6,146 3,170 1,285 
Net income$20,640 $10,590 $5,240 
Expenditures for long-lived assets(3)
$8,672 $5,561 $3,830 
(1) Early-stage research and development primarily includes costs incurred from discovery through Phase 2 clinical trials. Late-stage research and development primarily includes costs incurred from Phase 3 clinical trials.
(2) Other segment items primarily include income taxes and asset impairment, restructuring, and other special charges.
(3) Includes expenditures for property and equipment and computer software costs.